89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company specializing in treatments for liver and cardio-metabolic diseases, announced a corporate update at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 5:00 PM ET. The event will feature one-on-one investor meetings and a presentation accessible via the conference portal. The company's lead candidate, BIO89-100, targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). For more details, the webcast will be archived on 89bio’s investor section.

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10^th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 PM ET.

The presentation will be available through the SVB Leerink conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

When is 89bio's corporate update at the SVB Leerink conference?

89bio's corporate update is scheduled for February 25, 2021, at 5:00 PM ET.

What is 89bio's lead product candidate?

89bio's lead product candidate is BIO89-100, designed for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

Where can I access 89bio's presentation from the conference?

The presentation can be accessed through the SVB Leerink conference portal and will also be archived on 89bio’s website.

What therapy areas does 89bio focus on?

89bio focuses on innovative therapies for liver and cardio-metabolic diseases.

Is 89bio a publicly traded company?

Yes, 89bio is publicly traded on Nasdaq under the stock symbol ETNB.